Literature DB >> 15661623

Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine.

J D Salamone1, M Correa, S M Mingote, S M Weber.   

Abstract

According to the dopamine (DA) hypothesis of reward, DA systems in the brain, particularly in the nucleus accumbens, are thought to directly mediate the rewarding or primary motivational characteristics of natural stimuli such as food, water and sex, as well as various drugs of abuse. However, there are numerous problems associated with this hypothesis. Interference with accumbens DA transmission does not substantially blunt primary motivation for natural rewards such as food, but it does disrupt the propensity of animals to engage in effortful responding to obtain food. Electrophysiological and voltammetric studies indicate that novel stimuli, conditioned stimuli that predict reward, and instrumental behaviors that deliver natural rewards all act to stimulate DA activity. Accumbens DA acts as a modulator of several functions related to motivated behavior, and can influence normal and pathological cognitive function, activational aspects of motivation, anergia or psychomotor slowing in depression, the impact of conditioned stimuli, plasticity and a variety of sensorimotor functions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15661623     DOI: 10.1016/j.coph.2004.09.004

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  187 in total

Review 1.  The behavioral activation system and mania.

Authors:  Sheri L Johnson; Michael D Edge; M Kathleen Holmes; Charles S Carver
Journal:  Annu Rev Clin Psychol       Date:  2011-11-07       Impact factor: 18.561

Review 2.  Reconsidering anhedonia in depression: lessons from translational neuroscience.

Authors:  Michael T Treadway; David H Zald
Journal:  Neurosci Biobehav Rev       Date:  2010-07-11       Impact factor: 8.989

Review 3.  The role of rodent models in the discovery of new treatments for schizophrenia: updating our strategy.

Authors:  Holly Moore
Journal:  Schizophr Bull       Date:  2010-09-24       Impact factor: 9.306

4.  The TaqIA RFLP is associated with attenuated intervention-induced body weight loss and increased carbohydrate intake in post-menopausal obese women.

Authors:  Jameason D Cameron; Marie-Ève Riou; Frédérique Tesson; Gary S Goldfield; Rémi Rabasa-Lhoret; Martin Brochu; Éric Doucet
Journal:  Appetite       Date:  2012-09-29       Impact factor: 3.868

Review 5.  Dopamine and reward: the anhedonia hypothesis 30 years on.

Authors:  Roy A Wise
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

6.  Of Mice and Men: Natural Kinds of Emotions in the Mammalian Brain? A Response to Panksepp and Izard.

Authors:  Lisa Feldman Barrett; Kristen A Lindquist; Eliza Bliss-Moreau; Seth Duncan; Maria Gendron; Jennifer Mize; Lauren Brennan
Journal:  Perspect Psychol Sci       Date:  2007-09

7.  Affective status in relation to impulsive, motor and motivational symptoms: personality, development and physical exercise.

Authors:  Tomas Palomo; Richard J Beninger; Richard M Kostrzewa; Trevor Archer
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

8.  Transient inactivation of the ventral tegmental area selectively disrupts the expression of conditioned place preference for pup- but not cocaine-paired contexts.

Authors:  Katharine M Seip; Joan I Morrell
Journal:  Behav Neurosci       Date:  2009-12       Impact factor: 1.912

Review 9.  The debate over dopamine's role in reward: the case for incentive salience.

Authors:  Kent C Berridge
Journal:  Psychopharmacology (Berl)       Date:  2006-10-27       Impact factor: 4.530

10.  Adenosine A(2A) receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and effort-related choice in the rat: implications for studies of psychomotor slowing.

Authors:  Andrew M Farrar; Mariana Pereira; Francisco Velasco; Jörg Hockemeyer; Christa E Müller; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2006-10-27       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.